SN

Smith & Nephew appoints David King as Non-Executive Director

Smith & Nephew Plc announces the addition of David King as an independent Non-Executive Director, effective July 1, 2025, enhancing their healthcare leadership...

Smith & Nephew Plc 12-Point Plan increasingly delivering better financial performance

Smith & Nephew reports strong financial results for 2024 with significant revenue and profit growth, driven by innovation and strategic restructuring...

Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled...

Smith & Nephew Plc transforming into a higher growth and more profitable business

Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth...

Smith & Nephew Q1 trading update shows revenue growth and confident outlook

Smith+Nephew plc (LON:SN, NYSE:SNN) reports Q1 revenue of $1,386 million, up 2.9% underlying. Orthopaedics and Sports Medicine show strong growth. CEO confident in outlook...

Smith & Nephew reports Q4 revenue of $1,458 million, up 6.4%

Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024...

Smith+Nephew to attend AAOS 2024, showcasing leading Orthopaedic solutions

Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field...
Search

Funds

SN

Smith & Nephew appoints David King as Non-Executive Director

Smith & Nephew Plc announces the addition of David King as an independent Non-Executive Director, effective July 1, 2025, enhancing their healthcare leadership...

Smith & Nephew Plc 12-Point Plan increasingly delivering better financial performance

Smith & Nephew reports strong financial results for 2024 with significant revenue and profit growth, driven by innovation and strategic restructuring...

Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled...

Smith & Nephew Plc transforming into a higher growth and more profitable business

Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth...

Smith & Nephew Q1 trading update shows revenue growth and confident outlook

Smith+Nephew plc (LON:SN, NYSE:SNN) reports Q1 revenue of $1,386 million, up 2.9% underlying. Orthopaedics and Sports Medicine show strong growth. CEO confident in outlook...

Smith & Nephew reports Q4 revenue of $1,458 million, up 6.4%

Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024...

Smith+Nephew to attend AAOS 2024, showcasing leading Orthopaedic solutions

Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field...
Search

Funds

SN

FTSE 100

Funds